USE OF PREDICTIVE PROBABILITIES IN PHASE II AND PHASE III CLINICAL TRIALS

DOI10.1081/BIP-100101000zbMath0919.62120OpenAlexW2062041045WikidataQ52220712 ScholiaQ52220712MaRDI QIDQ4244517

John S. Andersen, Don Johns

Publication date: 5 September 1999

Published in: Journal of Biopharmaceutical Statistics (Search for Journal in Brave)

Full work available at URL: https://doi.org/10.1081/bip-100101000

zbMATH Keywords

beta-binomial distributiontherapeutic equivalenceinterim analyses

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10)

Related Items (3)

Uses, Abuses and Misuses of Significance Tests in the Scientific Community: Won't the Bayesian Choice be Unavoidable? ⋮ Implementing Bayesian predictive procedures: the \(K\)-prime and \(K\)-square distributions ⋮ A hybrid Bayesian-frequentist predictive design for monitoring multi-stage clinical trials

This page was built for publication: USE OF PREDICTIVE PROBABILITIES IN PHASE II AND PHASE III CLINICAL TRIALS